Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 136

1.

The Italian Pharmacovigilance Program: An Observational Study of Adverse Effects of Natalizumab in Multiple Sclerosis Therapy.

Giacoppo S, Ruscica M, Grimaldi LM, Bramanti P, Mazzon E.

Med Sci Monit. 2017 Sep 2;23:4230-4240.

2.

Prolonged Cerebrospinal Fluid Neurofilament Light Chain Increase in Patients with Post-Traumatic Disorders of Consciousness.

Bagnato S, Grimaldi LME, Di Raimondo G, Sant'Angelo A, Boccagni C, Virgilio V, Andriolo M.

J Neurotrauma. 2017 Aug 15;34(16):2475-2479. doi: 10.1089/neu.2016.4837. Epub 2017 Jun 8.

PMID:
28385104
3.

Assessment of brain core temperature using MR DWI-thermometry in Alzheimer disease patients compared to healthy subjects.

Sparacia G, Sakai K, Yamada K, Giordano G, Coppola R, Midiri M, Grimaldi LM.

Jpn J Radiol. 2017 Apr;35(4):168-171. doi: 10.1007/s11604-017-0616-0. Epub 2017 Feb 3.

PMID:
28160227
4.

Extubation Failure after Neonatal Cardiac Surgery: A Multicenter Analysis.

Mastropietro CW, Cashen K, Grimaldi LM, Narayana Gowda KM, Piggott KD, Wilhelm M, Gradidge E, Moser EAS, Benneyworth BD, Costello JM.

J Pediatr. 2017 Mar;182:190-196.e4. doi: 10.1016/j.jpeds.2016.12.028. Epub 2017 Jan 4.

PMID:
28063686
5.

No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).

Lanzillo R, Quarantelli M, Pozzilli C, Trojano M, Amato MP, Marrosu MG, Francia A, Florio C, Orefice G, Tedeschi G, Bellantonio P, Annunziata P, Grimaldi LM, Comerci M, Brunetti A, Bonavita V, Alfano B, Marini S, Brescia Morra V; ARIANNA study group.

Mult Scler. 2016 Aug;22(9):1163-73. doi: 10.1177/1352458515611222. Epub 2015 Oct 14.

PMID:
26466947
6.

Natalizumab in the pediatric MS population: results of the Italian registry.

Ghezzi A, Moiola L, Pozzilli C, Brescia-Morra V, Gallo P, Grimaldi LM, Filippi M, G GC; MS Study Group-Italian Society of Neurology.

BMC Neurol. 2015 Sep 25;15:174. doi: 10.1186/s12883-015-0433-y.

7.

Trace elements in scalp hair samples from patients with relapsing-remitting multiple sclerosis.

Tamburo E, Varrica D, Dongarrà G, Grimaldi LM.

PLoS One. 2015 Apr 9;10(4):e0122142. doi: 10.1371/journal.pone.0122142. eCollection 2015.

8.

A pilot study on the use of interferon beta-1a in early Alzheimer's disease subjects.

Grimaldi LM, Zappalà G, Iemolo F, Castellano AE, Ruggieri S, Bruno G, Paolillo A.

J Neuroinflammation. 2014 Feb 13;11:30. doi: 10.1186/1742-2094-11-30.

9.

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, Olsson TP, Benamor M, Bauer D, Truffinet P, Church M, Miller AE, Wolinsky JS, Freedman MS, O'Connor P; TENERE Trial Group.

Mult Scler. 2014 May;20(6):705-16. doi: 10.1177/1352458513507821. Epub 2013 Oct 14.

PMID:
24126064
10.

Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases.

Ghezzi A, Pozzilli C, Grimaldi LM, Moiola L, Brescia-Morra V, Lugaresi A, Lus G, Rinaldi F, Rocca MA, Trojano M, Bianchi A, Comi G, Filippi M; Italian MS Study Group.

Mult Scler. 2013 Jul;19(8):1106-12. doi: 10.1177/1352458512471878. Epub 2013 Feb 11.

PMID:
23401129
11.

MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis.

Grimaldi LM, Prosperini L, Vitello G, Borriello G, Fubelli F, Pozzilli C.

Mult Scler. 2012 Sep;18(9):1337-9. doi: 10.1177/1352458512439438. Epub 2012 Mar 2.

PMID:
22389413
12.

The molecular anatomy of human Hsp60 and its similarity with that of bacterial orthologs and acetylcholine receptor reveal a potential pathogenetic role of anti-chaperonin immunity in myasthenia gravis.

Gammazza AM, Bucchieri F, Grimaldi LM, Benigno A, de Macario EC, Macario AJ, Zummo G, Cappello F.

Cell Mol Neurobiol. 2012 Aug;32(6):943-7. doi: 10.1007/s10571-011-9789-8. Epub 2012 Jan 19.

PMID:
22258649
13.

Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone.

Martinelli V, Cocco E, Capra R, Salemi G, Gallo P, Capobianco M, Pesci I, Ghezzi A, Pozzilli C, Lugaresi A, Bellantonio P, Amato MP, Grimaldi LM, Trojano M, Mancardi GL, Bergamaschi R, Gasperini C, Rodegher M, Straffi L, Ponzio M, Comi G; Italian Mitoxantrone Group.

Neurology. 2011 Nov 22;77(21):1887-95. doi: 10.1212/WNL.0b013e318238ee00. Epub 2011 Nov 9.

PMID:
22076543
14.

Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II).

Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, Cilia S, Cottone S, Grimaldi LM; COGIMUS study group.

Qual Life Res. 2012 Sep;21(7):1111-21. doi: 10.1007/s11136-011-0021-6. Epub 2011 Sep 28.

PMID:
21953022
15.

Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial.

Smolders J, Hupperts R, Barkhof F, Grimaldi LM, Holmoy T, Killestein J, Rieckmann P, Schluep M, Vieth R, Hostalek U, Ghazi-Visser L, Beelke M; SOLAR study group.

J Neurol Sci. 2011 Dec 15;311(1-2):44-9. doi: 10.1016/j.jns.2011.04.013. Epub 2011 May 28.

PMID:
21620416
16.

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological Society.

Ghezzi A, Grimaldi LM, Marrosu MG, Pozzilli C, Comi G, Bertolotto A, Trojano M, Gallo P, Capra R, Centonze D, Millefiorini E, Sotgiu S, Brescia Morra V, Amato MP, Lugaresi A, Mancardi G, Caputo D, Montanari E, Provinciali L, Durelli L, Bergamaschi R, Bellantonio P, Tola MR, Cottone S, Savettieri G, Tedeschi G; MS-SIN Study Group.

Neurol Sci. 2011 Apr;32(2):351-8. doi: 10.1007/s10072-010-0469-0.

PMID:
21234775
17.

Analyzing histopathological features of rare charcot-marie-tooth neuropathies to unravel their pathogenesis.

Benedetti S, Previtali SC, Coviello S, Scarlato M, Cerri F, Di Pierri E, Piantoni L, Spiga I, Fazio R, Riva N, Natali Sora MG, Dacci P, Malaguti MC, Munerati E, Grimaldi LM, Marrosu MG, De Pellegrin M, Ferrari M, Comi G, Quattrini A, Bolino A.

Arch Neurol. 2010 Dec;67(12):1498-505. doi: 10.1001/archneurol.2010.303.

PMID:
21149811
18.

Safety and efficacy of natalizumab in children with multiple sclerosis.

Ghezzi A, Pozzilli C, Grimaldi LM, Brescia Morra V, Bortolon F, Capra R, Filippi M, Moiola L, Rocca MA, Rottoli M, Sarchielli P, Zaffaroni M, Comi G.

Neurology. 2010 Sep 7;75(10):912-7. doi: 10.1212/WNL.0b013e3181f11daf.

PMID:
20820002
19.

Three years of experience: the Italian registry and safety data update.

Mancardi GL, Tedeschi G, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, Rossi P, Savettieri G, Tola MR, Comi G, Pozzilli C, Bertolotto A, Marrosu MG, Grimaldi LM, Laroni A, Vanacore N, Covezzoli A, De Rosa M, Piccinni C, Montanaro N, Periotto L, Iommelli R, Tomino C, Provinciali L.

Neurol Sci. 2011 Jan;31 Suppl 3:295-7. doi: 10.1007/s10072-010-0356-8.

PMID:
20644975
20.

Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study.

Sangalli F, Moiola L, Bucello S, Annovazzi P, Rizzo A, Radaelli M, Vitello G, Grimaldi LM, Ghezzi A, Martinelli V, Comi G.

Neurol Sci. 2011 Jan;31 Suppl 3:299-302. doi: 10.1007/s10072-010-0344-z.

PMID:
20544247

Supplemental Content

Loading ...
Support Center